转自：中国反邪教 【健康提醒！#止痛药不要随便吃#】#吃止痛药真的会上瘾吗# 生活中，很多人在头痛、关节痛时，选 择吃片止痛药来缓解。对此，专家提醒，常见止痛药的作用是控制疼痛症状，没办法消除引发疼痛的病 因。如果长期乱吃止痛药，可能会把身体的真实病情掩盖住，错过最佳的治疗时机。不过，针对癌痛患 者，长期规范地使用止痛药，是可以有效缓解疼痛、提升生活质量的。很多人担心吃止痛药会上瘾，专 家也对此进行了澄清：止痛药的成瘾性主要和阿片类止痛药的长期使用有关，比如吗啡、羟考酮，这类 药物国家有严格的管理规定，必须在医生指导下规范使用。而平时头疼、关节痛常用的对乙酰氨基酚、 布洛芬、塞来昔布等，并不存在成瘾性。 （央视网） （来源：中国反邪教） ...

北京大学第三医院主任医师 李水清：要根据不同的病因使用相应的止痛药物，像肌肉关节来源的疼 痛，可以使用非甾体抗炎药，如塞来昔布。对于带状疱疹引起的神经痛，可以用普瑞巴林等这类治疗神 经痛的药物。 （央视财经《第一时间》）生活中，很多人在头痛、关节痛时，选择吃片止痛药来缓解。对此，专家发 出提醒：止痛药不能随意吃、长期吃。 专家介绍，常见止痛药的作用是控制疼痛症状，没办法消除引发疼痛的病因。如果长期乱吃止痛药，可 能会把身体的真实病情掩盖住，错过最佳的治疗时机。不过，针对癌痛患者，长期规范地使用止痛药， 是可以有效缓解疼痛、提升生活质量的。 北京大学第三医院主任医师 李水清：像突然出现的剧烈头痛，或者头痛的时候伴随发烧、恶心、呕 吐、意识不清、手脚麻木等这些情况，需要及时就医。另外，如果头痛的性质、部位和规律发生改变， 也一定要及时到医院就医，避免延误病情。 转载请注明央视财经 编辑：孙艺璇 很多人担心吃止痛药会上瘾，专家也对此进行了澄清：止痛药的成瘾性主要和阿片类止痛药的长期使用 有关，比如吗啡、羟考酮，这类药物国家有严格的管理规定，必须在医生指导下规范使用。而平时头 疼、关节痛常用的对乙酰氨基酚、布洛芬、塞 ...

（原标题：止痛药上瘾？国家卫健委答21：不能长期任意吃，以下药合理使用） 北京大学第三医院主任医师李水清回应，止痛药不能长期任意吃。原因有以下几条：因为有一些止痛药 主要是控制症状，并不能消除病因，长期止痛药的使用，可能在某种程度上会掩盖病情，耽误治疗。当 然，对于一些癌痛的患者来讲，长期规范的药物使用可以缓解疼痛，提高他们的生活质量。另外，针对 不同的疼痛来讲，要根据不同的病因来使用相应止痛药物，像肌肉关节的疼痛，可以使用非甾体抗炎 药，像塞来昔布、双氯酚酸钠等。对于带状疱疹引起的神经痛，可以用普瑞巴林、克利加巴林等这类治 疗神经痛的药物。 另外，止痛药长期使用会不会上瘾。这主要是指一些阿片类的止痛药，像吗啡、羟考酮，长期使用可能 会有上瘾的问题。但是我们国家针对这一类型的药物有非常严格的管理制度，另外在医院里面，如果按 照医生的指导来规范使用的话，成瘾性就会大大降低。像日常用到的布洛芬、塞来昔布、对乙酰氨基酚 等这些非甾体抗炎药，一般没有成瘾的问题，但是剂量加大的话，疗效不会增加，副作用会增加，这方 面要引起重视。 关于头痛的问题，李水清举例说，像有些偏头痛如果反复发作，诱因比较明确的话，比如一些患者睡眠 ...

止痛药长期使用会不会上瘾？李水清说，这主要是指一些阿片类的止痛药，像吗啡、羟考酮，长期 使用可能会有上瘾的问题。我国针对这一类型的药物有非常严格的管理制度，在医院，如果按照医生的 指导来规范使用的话，成瘾性就会大大降低。日常用到的布洛芬、塞来昔布、对乙酰氨基酚等这些非甾 体抗炎药，一般没有成瘾的问题，但是剂量加大的话，疗效不会增加，副作用会增加，这方面要引起重 视。 关于头痛的问题，李水清说，像有些偏头痛如果反复发作，诱因比较明确的话，比如一些患者睡眠 不足、睡眠过度，或者吃了一些特殊食物以后会诱发，找到并避开这些诱因可以减少偏头痛的发作。但 是有一些头痛不仅让人感到非常痛苦，而且它是身体发出的求救的信号，像突然出现的剧烈头痛，或者 头痛的时候伴随发烧、恶心、呕吐、意识不清、手脚麻木等等这些情况，就需要及时就医。另外，如果 头痛的性质、部位和频率发生改变，也一定要及时到医院来就医，避免延误病情。 人民网北京12月19日电 （记者乔业琼）生活中，不少人遇到过疼痛的困扰。有的人一头痛、关节 痛就吃止痛药。而有的人认为"头痛扛一扛就过去"，也有人认为"经常吃止痛药会上瘾"。在国家卫生健 康委今日召开的新闻发布会上， ...

Group 1 - The use of sedatives in ICU is essential to manage patients' anxiety, tension, and fear, which can hinder treatment and increase oxygen consumption, affecting recovery success rates [2][4] - Common sedatives used in ICU include Diazepam, Midazolam, Propofol, and Dexmedetomidine, which help patients through critical phases of illness by inducing a state similar to deep sleep, with full cognitive recovery after the drug effects wear off [3][4] - The administration of sedatives is strictly controlled in terms of dosage and duration to prevent dependency, with studies indicating that long-term cognitive impairment in critically ill patients is more related to the severity of illness rather than the sedatives themselves [4] Group 2 - Opioid analgesics such as Codeine, Hydrocodone, Oxycodone, Morphine, Sufentanil, and Remifentanil are also used in ICU, providing strong pain relief but with potential for addiction, necessitating careful monitoring by healthcare professionals [3][4] - Individualized sedation strategies are implemented based on patient-specific factors like weight and organ function, ensuring comfort during treatment while safeguarding long-term cognitive health [4]

Core Viewpoint - Enhua Pharmaceutical (002262) has shown steady growth in its core products, with a focus on expanding its new drug pipeline and enhancing research and development efforts, leading to a "buy" rating from Pacific Securities [1][4]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 3.01 billion yuan, a year-on-year increase of 8.93% [2]. - The net profit attributable to shareholders was 700 million yuan, reflecting a year-on-year growth of 11.38% [2]. - Basic earnings per share (EPS) reached 0.69 yuan, up 11.29% year-on-year [2]. Product Growth - The company has leveraged its product differentiation advantages to achieve stable growth in mature products while rapidly promoting new products [3]. - Anesthesia products generated revenue of 1.63 billion yuan, accounting for 54.29% of total revenue, with a year-on-year growth of 7.32% [3]. - Mental health products reported revenue of 621 million yuan, representing 20.63% of total revenue, with a year-on-year increase of 4.29% [3]. - Neurology products saw significant growth, with revenue of 166 million yuan, a year-on-year increase of 107.33% [3]. Research and Development - The company invested 395 million yuan in R&D in the first half of 2025, a year-on-year increase of 23.97%, representing 13.12% of revenue [4]. - There are currently 17 innovative drug projects under development, with various clinical trial phases completed and ongoing [4]. Profit Forecast and Investment Rating - Revenue projections for 2025-2027 are 6.40 billion, 7.26 billion, and 8.24 billion yuan, with year-on-year growth rates of 12.39%, 13.34%, and 13.51% respectively [4]. - Net profit forecasts for the same period are 1.29 billion, 1.48 billion, and 1.69 billion yuan, with growth rates of 13.19%, 14.03%, and 14.56% respectively [4]. - The current stock price corresponds to a price-to-earnings (PE) ratio of 17, 15, and 13 for 2025-2027 [4].

Core Viewpoint - The company reported a strong performance in the first half of 2025, with significant revenue and profit growth, driven by robust sales of core products and rapid growth in new products [1][2]. Financial Performance - In the first half of 2025, the company achieved operating revenue of 3.01 billion yuan, a year-on-year increase of 8.93% [1] - The net profit attributable to shareholders was 700 million yuan, reflecting a year-on-year growth of 11.38% [1] - Basic earnings per share (EPS) reached 0.69 yuan, up 11.29% year-on-year [1] Product Performance - Anesthesia products generated revenue of 1.63 billion yuan, accounting for 54.29% of total revenue, with a year-on-year growth of 7.32% [1] - Mental health products achieved revenue of 621 million yuan, representing 20.63% of total revenue, with a year-on-year increase of 4.29% [1] - Neurology products saw revenue of 166 million yuan, making up 5.51% of total revenue, with a remarkable year-on-year growth of 107.33% [1] R&D Investment - The company invested 395 million yuan in R&D in the first half of 2025, a year-on-year increase of 23.97%, representing 13.12% of total revenue [2] - There are currently 17 innovative drug projects in the pipeline, indicating a rich new drug pipeline [2] - The company has completed one Phase III clinical study and two Phase II studies, with additional studies ongoing [2] Profit Forecast - Projected operating revenues for 2025-2027 are 6.40 billion, 7.26 billion, and 8.24 billion yuan, with year-on-year growth rates of 12.39%, 13.34%, and 13.51% respectively [2] - Expected net profits for the same period are 1.29 billion, 1.48 billion, and 1.69 billion yuan, with growth rates of 13.19%, 14.03%, and 14.56% respectively [2] - EPS forecasts for 2025-2027 are 1.27, 1.45, and 1.66 yuan, with corresponding PE ratios of 17, 15, and 13 times [2]

Core Viewpoint - The company reported a strong performance in the first half of 2025, with revenue and net profit showing positive growth compared to the previous year [1][2]. Financial Performance - In H1 2025, the company achieved revenue of 3.01 billion yuan (+8.93%) and a net profit attributable to shareholders of 700 million yuan (+11.38%) [1]. - For Q2 2025, revenue was 1.50 billion yuan (+6.64%) with a net profit of 400 million yuan (+9.94%) [1]. Segment Performance - The pharmaceutical industry revenue reached 2.58 billion yuan (+9.52%), while commercial pharmaceutical revenue was 394 million yuan (+9.80%) [2]. - Anesthesia revenue was 1.63 billion yuan (+7.32%), CNS revenue was 166 million yuan (+107.33%), and raw material drug revenue was 90 million yuan (-6.17%) [2]. R&D and Innovation - The company has a robust pipeline with 17 innovative drug projects in development, including NH600001, which is expected to be approved in 2026 [2]. - R&D expenses increased by 11.36% in H1 2025, indicating a commitment to innovation [2]. Strategic Focus - The company is enhancing market access for new anesthesia products, with significant growth expected for the newly approved drug, fumaric acid oseltamivir [3]. - The CNS product line is being refined, with promising growth anticipated for the new drug, Antitan [3]. - The company is expanding its pipeline and commercial layout through the launch of new products and a rich innovation reserve [3]. Profit Forecast - The adjusted net profit forecasts for 2025-2026 are 1.32 billion yuan and 1.52 billion yuan, respectively, with an expected net profit of 1.76 billion yuan in 2027 [3].

Group 1 - The Gaza authorities reported the discovery of opioids, specifically Oxycodone, in flour bags distributed at U.S. and Israeli aid points, raising concerns about public health risks [1][3] - The Gaza media office accused Israel of being responsible for this act, claiming it is part of a broader strategy to undermine Palestinian society and constitutes a form of genocide [3] - Allegations were made that the Israeli military is using the blockade to smuggle these substances disguised as aid, labeling the aid centers as "death traps" [3][4] Group 2 - The humanitarian organization "Gaza Humanitarian Foundation" (GHF), supported by the U.S. and Israel, has been criticized for causing civilian casualties, with reports indicating at least 46 individuals were killed by Israeli fire while waiting for aid [4] - The UN has condemned the militarization of humanitarian aid by Israel, stating it violates international aid distribution standards and could constitute war crimes [4] - As of June 27, the Palestinian health department reported over 6,000 deaths and nearly 21,000 injuries due to Israeli attacks since March 18, highlighting the ongoing humanitarian crisis in Gaza [5]

Group 1: Company Performance and Sales - The company achieved approximately 1 billion in sales for Antitan after leveraging its sales channel advantages [2] - Oxycodone generated nearly 5 billion in revenue last year, indicating strong market performance [2] - The sales target for Midazolam injection in 2024 is projected to reach around 7 billion [2] - The company expects a sales figure of 2 billion for Oligo in 2025, with over 1,500 hospitals anticipated to adopt the product [1] Group 2: Market Strategy and International Expansion - Domestic sales account for 98.55% of total sales, while international sales represent only 0.41% [1] - The company plans to accelerate international expansion through external product introductions and self-developed project licensing [1] - The company is focusing on strategic partnerships and licensing opportunities to enhance its international presence [4] Group 3: Product Development and Pipeline - NH600001 is progressing well, with NDA submission expected in the second half of this year and approval anticipated in the first half of 2027 [1] - The company is developing long-acting formulations, including Aripiprazole long-acting injection, currently in clinical stages [3] - NH102, NH130, and NH160030 are innovative drug projects in clinical phases, targeting depression and Parkinson's disease symptoms [4] Group 4: Market Challenges and Regulatory Impact - The company acknowledges ongoing challenges in the pain management sector due to competition from other firms [1] - The impact of national procurement policies on the company's operations is considered minimal, but local procurement remains uncertain [2] - The company aims for double-digit growth despite the challenges posed by procurement policies [2] Group 5: Future Outlook and Growth Projections - The company anticipates double-digit growth in the anesthesia, mental health, and neurological sectors [6] - Strategic focus on core competencies is expected to enhance competitive advantages in the market [7] - The company is optimistic about achieving a robust growth trajectory over the next 3-5 years [4]